XenoGesis, which specialises in preclinical drug metabolism and pharmacokinetics (DMPK), Molecular Profiles said their collaboration will offer drug developers a better understanding of a compound’s bioavailability and help them select compounds for DMPK and ADME (absorption, distribution, metabolism and elimination) studies. It will also help customers solve solubility problems during formulation development, they said.
The industry is seeing a slowly developing uptick in preclinical testing that this partnership may benefit from.
Claire Madden-Smith, commercial director, Molecular Profiles, told Outsourcing-Pharma.com her company had teamed up with XenoGesis because of its “impressive expertise” as well as its proximity; both companies are based in the city of Nottingham, England.
“Really, they are clear experts in the DMPK preclinical side and they bring that biological expertise, while Molecular Profiles brings that chemistry and pharmaceutics expertise in developing the formulations. Both are important and require linked-up understanding," she said.
“To be able to offer that to our clients in a co-ordinated and synergistic way is very valuable. There are obviously lots of different companies out there with different strengths – some in pharmacokinetics or bioanalysis, but it’s maybe a little more unusual for such an early phase offering to have all that combined.”
Poorly water-soluble molecules
Madden-Smith added, “The big thing we are working on right now is bringing up our expanding and enabling technology. We’re bringing on GMP hot melt extrusion equipment, and that’s really gearing up to handle poorly water-soluble molecules.
“Something like 70% of new chemical entities are poorly water-soluble. We’re looking at what are the viable ways to formulate poorly water soluble materials.”
She said the company’s screening technology works using very small amounts of materials, and so can quickly give feedback to clients on advisable formulation pathways.